Biomarkers Consortium - The Performance of Novel Cardiac Biomarkers in the General U.S. Population

The Biomarkers Consortium’s Novel Cardiac Biomarkers in the General US Population (the Cardiac Troponin Project) seeks to define the reference ranges and to generate the epidemiologic basis for the use of several significant novel cardiac and related biomarkers for cardiovascular risk stratification in the general U.S. population. The program will measure a panel of biomarkers in almost 30,000 individuals in a national study. The project will provide key reference data regarding novel biomarkers for cardiovascular risk stratification and inform U.S. clinical and laboratory guidelines.


  • Define the reference ranges of hs-cTnT, hs-cTnI, and NT-proBNP in a young, healthy subgroup of adults (N=1,938) and describe age-, gender- and race-specific population values.
  • Characterize the associations of hs-cTnT, hs-cTnI, and NT-proBNP with cardiovascular and total mortality in the U.S. population without clinical cardiovascular disease and to conduct a head-to-head comparison of hs-cTnT to hs-cTnI for mortality risk prediction.

Anticipated Results:

Peer reviewed publications and final dataset made publicly available on NHANES' website


Public-Sector Partners:
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
U.S. Food and Drug Administration (FDA)

Private-Sector Partners:
Abbott Labs*
AstraZeneca Pharmaceuticals LP*
Janssen L.P.
Johnson & Johnson*
Ortho Clinical Diagnosistics*
National Dairy Institute*
Roche Diagnostics*
Siemens Healthcare Diagnostics Inc.*

Academic Partners:
Johns Hopkins University
University of Maryland
University of Vermont

*Provided financial or in-kind support for this program.

FNIH Contact

Helen Heymann, MMSC, Scientific Project Manager, Metabolic Disorders;